Answer: Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications that includes semaglutide (Wegovy, Ozempic, Rybelsus), tirzepatide (Zepbound, Mounjaro), liraglutide (Victoza, Saxenda), and orforglipron (Foundayo), have become increasingly popular for obesity treatment (Mehrtash, JAMA Intern Med 2025)
If a Healthy Connections provider determines that GLP-1 treatment may be appropriate, the provider must prescribe an eligible medication and complete the required prior authorization
Thus, these conserved interactions promote the formation and stability of the bypass motif, which is a key structural determinant for the high potency of Amy analogues at AMYRs 15,16
If your dose has not been adjusted in a long time and weight loss has stalled or reversed, a dosage review may be warranted